title: [Clinical and morphologic efficacy of a complex antioxidant and energy correction therapy of different duration in brain infarction: results of a multicenter randomized trial].
abstract: OBJECTIVE
  To compare clinical and morphological results of treatment of ischemic stroke in three groups of patients which differed by the forms and duration of an antioxidant therapy.
  
  
  METHODS
  A randomized clinical trial was performed in 8 vascular centers of the Russian Federation in 2010-2014. It included 373 patients with ischemic stroke in the carotid territory. Patients were randomized into 3 groups to receive different regimens of antioxidant therapy as an adjunct to standard therapy: control group (ascorbic acid; 132 patients); cytoflavin (20 ml per day for 10 days; 133 patients); cytoflavin (the dose was decreased to 10 ml per day from 11th to 20th day) (108 patients). Patient's condition was assessed in 1, 10 and 21 day by a complex of clinical, laboratory and instrumental methods.
  
  
  CONCLUSIONS
  The analysis of CT in 1th and 21th day revealed a significant 1,5-1,7- fold decrease in the cerebral ischemic lesion in both groups treated with cytoflavin with no significant morphologic changes in the ascorbic acid group. The percentage of patients with ischemic lesion, increased during days 1-21, was 2-fold higher in the ascorbic acid group compared to cytoflavin groups. Morphologic changes were correlated with clinical variables and outcome. In patients with ≥14 points on NIH scale on admission, prolonged 20 day cytoflavin therapy was associated with a more prominent improvement of neurologic, functional and cognitive status compared to 10-day cytoflavin infusion. No differences in clinical variables were observed in patients with mild symptoms (<14 points on NIH scale on admission) receiving cytoflavin for 10 and 20 days.
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: S A
authors.initials: SA
authors.lastname: Rumyantsevа
authors.affiliation: Institute of toxicology of Federal Medical Biological Agency, St. Petersburg.
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
authors.affiliation: Sechenov First Moscow State Medical University, Moscow.
authors.forename: E V
authors.initials: EV
authors.lastname: Silinа
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: V A
authors.initials: VA
authors.lastname: Stupin
authors.affiliation: Institute of toxicology of Federal Medical Biological Agency, St. Petersburg.
authors.forename: E N
authors.initials: EN
authors.lastname: Kabaeva
authors.affiliation: Tver State Medical Academy, Tver.
authors.forename: L V
authors.initials: LV
authors.lastname: Chichanovskaya
authors.affiliation: Tver State Medical Academy, Tver.
authors.forename: M V
authors.initials: MV
authors.lastname: Nazarov
authors.affiliation: Ochapovsky Regional Clinical Hospital #1, Krasnodar.
authors.forename: L A
authors.initials: LA
authors.lastname: Tsukurova
authors.affiliation: City policlinic #12, Moscow.
authors.forename: D V
authors.initials: DV
authors.lastname: Burenichev
authors.affiliation: City General Hospital #2, St. Petersburg.
authors.forename: K V
authors.initials: KV
authors.lastname: Golikov
authors.affiliation: City General Hospital #2, St. Petersburg.
authors.forename: M V
authors.initials: MV
authors.lastname: Salnikov
authors.affiliation: Ulyanovsk State University, Ulyanovsk, Central Medical Departament, Ulyanovsk.
authors.forename: L A
authors.initials: LA
authors.lastname: Belova
authors.affiliation: Ulyanovsk State University, Ulyanovsk, Central Medical Departament, Ulyanovsk.
authors.forename: V V
authors.initials: VV
authors.lastname: Mashin
authors.affiliation: Kirov State Medical Academy, Kirov.
authors.forename: N K
authors.initials: NK
authors.lastname: Mazina
authors.affiliation: Kirov State Medical Academy, Kirov.
authors.forename: E A
authors.initials: EA
authors.lastname: Zhilina
authors.affiliation: Ulyanovsk State University, Ulyanovsk, Central Medical Departament, Ulyanovsk.
authors.forename: O Yu
authors.initials: OY
authors.lastname: Kolotik-Kameneva
authors.affiliation: Kirov State Medical Academy, Kirov.
authors.forename: M A
authors.initials: MA
authors.lastname: Sherman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D020520:Brain Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D004338:Drug Combinations; D004734:Energy Metabolism; D005260:Female; D005486:Flavin Mononucleotide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007290:Inosine Diphosphate / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D012426:Russia; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate; D001205:Ascorbic Acid